XGN Delivers Record Revenue and Higher Margins in Q3 2025: Focus Shifts to Pathway for Profitability
Strong Revenue Growth Sets the Tone for Exagen's Quarter
Exagen Inc. (NASDAQ:XGN) reported a milestone third quarter for 2025, with revenue surging to $17.24 million—a 38% year-over-year increase compared to Q3 2024. This marked the company’s highest quarterly revenue on record, driven by both greater demand for AVISE CTD testing and improved pricing.
AVISE CTD test volume grew 16% year-over-year, while the average selling price (ASP) climbed to $441, a $37 gain over last year’s figure. Exagen also finished the quarter with $35.7 million in cash and cash equivalents, reflecting robust cash management and strengthening its position for ongoing operations and R&D investments.
Profitability Remains Elusive but Margin Improvement Signals Progress
While XGN continues to operate at a net loss, the latest numbers show meaningful improvement on the bottom line. Gross margin advanced to 58.4% (from 55.8% a year ago), thanks to the pricing uptick and greater economies of scale. Adjusted EBITDA—a measure the company emphasizes to show operating trends—narrowed to -$1.90 million for the quarter, a notable improvement from -$4.02 million in Q3 2024.
Here’s a summary table of key metrics from Q3:
| Metric | Q3 2025 | Q3 2024 | Y/Y Change |
|---|---|---|---|
| Revenue ($000) | 17,244 | 12,507 | +38% |
| Gross Margin | 58.4% | 55.8% | +2.6 pts |
| Net Loss ($000) | (7,087) | (5,028) | N/A |
| Adjusted EBITDA ($000) | (1,895) | (4,024) | Improved |
| Cash & Equivalents ($000) | 35,652 | 22,035 | +62% |
| Trailing-12M ASP ($) | 441 | 404 | +9.2% |
Test Portfolio Expansion and Conference Activity Reinforce Strategic Focus
XGN continues to expand its autoimmune diagnostics portfolio, commercially launching seronegative rheumatoid arthritis markers for anti-PAD4 in Q3. The company also made a notable showing at the American College of Rheumatology Conference with six scientific abstracts and a plenary presentation spotlighting advancements in lupus nephritis diagnostics.
This ongoing innovation and visibility are central to the company’s growth strategy—broadening clinical adoption while building scientific credibility in a competitive market.
Guidance Reiterated: Eye on Full-Year Revenue Target and Positive EBITDA
Looking forward, Exagen reaffirmed its full-year 2025 revenue guidance in the $65–$70 million range. At the upper end of that guidance, the company expects to reach positive adjusted EBITDA in the fourth quarter. This pathway to operating profitability hinges on sustained test volume growth, further ASP gains, and careful expense management.
The balance sheet remains a bright spot: cash and equivalents climbed $13.6 million over the past year, and total stockholders’ equity nearly doubled since year-end 2024.
| Balance Sheet Item | 9/30/2025 | 12/31/2024 | Change |
|---|---|---|---|
| Cash & Cash Equivalents ($000) | 35,652 | 22,036 | +62% |
| Total Assets ($000) | 62,823 | 44,689 | +41% |
| Total Liabilities ($000) | 44,685 | 35,149 | +27% |
| Total Stockholders' Equity ($000) | 18,138 | 9,540 | +90% |
Bottom Line: Operational Momentum and Financial Improvement Drive Confidence
Exagen’s third-quarter results offer a mix of robust growth, improved financial discipline, and renewed strategic clarity. With rising ASPs, expanded testing capabilities, and cash on hand to fuel further innovation, XGN is progressing toward break-even despite the sector’s inherent reimbursement and regulatory challenges.
For investors, the company’s reiterated outlook and tightening adjusted EBITDA loss underscore an inflection point worth watching in upcoming quarters. Will volume, price, and expense trends be enough to cross into sustained profitability? With new tests and expanding clinical visibility, the road ahead is one to track closely.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI